Intended Audience: Physicians, Nurse Practitioners, Physician Assistants, Pharmacists, and Nurses
Exacerbations, lung function, medication use, daily activities – there are many ways in which asthma control can be assessed. In this CE-accredited webcast, expert faculty take a close look at how providers, patients, and payers are defining asthma control, and how new therapies are showing promise to improve patient outcomes. Patient scenarios illustrate clinical conundrums often faced by payer organizations and providers in daily practice and provide an opportunity to explore the implications of biomarkers, comorbidities, and patient factors for treatment decision-making.
Physicians completing this program will earn AMA PRA Category 1 Credit™ classified as Enduring material.
Pharmacists completing this program will earn Home Study credit in Disease State Mgmt/Drug therapy (H01).
This activity is provided by PRIME Education. There is no fee to participate. This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
At PRIME, we are committed to ensuring that individuals with disabilities can access all of the content offered by PRIME through our website and other properties. If you are having trouble accessing primeinc.org, please email email@example.com for assistance. Please put “ADA Inquiry” in the subject line of your email.
Activity Type: Online Release Date:July 1, 2019 Expiration Date:June 30, 2020Total Price:Free
Continuing Education Credits:
- 1.0 CE for Physicians (AMA Category 1)
- 1.0 CE for Physician Assistants
- 1.0 CE for Nurse Practitioners
- 1.0 CE for Pharmacists (Automatic NABP)
- 1.0 CE for Nurses
• Estimated time to complete: 60 minutes
• Content last reviewed July 1, 2019.
• You do not need to complete in one sitting.
David I Bernstein, MD, FAAAAI, FACAAI, FACP Professor of Medicine and Environmental Health
Division of Immunology, Allergy, and Rheumatology
University of Cincinnati College of Medicine
Co-Director, Allergy Fellowship Program
Director, University Hospital Allergy Clinic
Eric Cannon, PharmD, FAMCP Assistant Vice President
Pharmacy Benefit Services
Salt Lake City, UT
Allan J Chernov, MD Medical Director (Retired)
Mid-Markets and Medical Policy
Blue Cross and Blue Shield of Texas (BCBSTX)
Heidi Wynn Maloni, PhD, ANP-BC, CNRN, MSCN National Clinical Nursing Director
Multiple Sclerosis Center of Excellence East
Veterans Affairs Medical Center
Joyce M Knestrick, PhD, CRNP, FAANP Associate Professor
Family Nurse Practitioner
Wheeling Health Right
I. A Comprehensive Look at Asthma Control
II. Defining Clinically-Relevant Asthma Subtypes
III. Differentiating New and Emerging Asthma Therapies
IV. Putting It All Together: Using Biomarkers and Clinical Parameters to Guide Therapy Selection
- Assess clinical measures of asthma control—including exacerbations, lung function, quality of life, and oral corticosteroid use—to guide managed care decision-making on treatment response and necessary adjustments
- Differentiate the indications, efficacy and safety profiles, and utility of new and emerging biologic therapies for uncontrolled, moderate-to-severe asthma
- Develop frameworks for applying biomarker testing, comorbidities, and other clinical factors to appropriate selection of different biologic therapies for patients with asthma